Katrin Beyer

List of Publications by Year
in descending order

54	2,189	279701 23	233338 45
papers	citations	h-index	g-index

57	57	57	3851
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic landscape of Segawa disease in Spain. Long-term treatment outcomes. Parkinsonism and Related Disorders, 2022, 94, 67-78.	1.1	1
2	Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 725.	1.8	7
3	Platelet miRNA Biosignature Discriminates between Dementia with Lewy Bodies and Alzheimerâ€™s Disease. Biomedicines, 2021, 9, 1272.	1.4	8
4	Alternative platelet activation pathways and their role in neurodegenerative diseases. Neurobiology of Disease, 2021, 159, 105512.	2.1	14
5	Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy. International Journal of Molecular Sciences, 2020, 21, 4718.	1.8	15
6	Comprehensive proteomic profiling of plasma-derived Extracellular Vesicles from dementia with Lewy Bodies patients. Scientific Reports, 2019, 9, 13282.	1.6	16
7	Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimerâ€™s disease and dementia with Lewy bodies. Translational Neurodegeneration, 2019, 8, 31.	3.6	112
8	Glucocerebrosidase regulators SCARB2 and TFEB are up-regulated in Lewy body disease brain. Neuroscience Letters, 2019, 706, 164-168.	1.0	2
9	Extracellular vesicles, new actors in the search for biomarkers of dementias. Neurobiology of Aging, 2019, 74, 15-20.	1.5	32
10	Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder. Parkinsonism and Related Disorders, 2018, 50, 94-98.	1.1	23
11	The long-lived Octodon degus as a rodent drug discovery model for Alzheimer's and other age-related diseases. , 2018, 188, 36-44.		21
12	P1â€293: IDENTIFICATION OF EXOSOMAL MICRORNAS AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P398.	0.4	0
13	Glucocerebrosidase mRNA is Diminished in Brain of Lewy Body Diseases and Changes with Disease Progression in Blood. , 2018, 9, 208.		14
14	INDEL Length and Haplotypes in the Î²-Synuclein Gene: A Key to Differentiate Dementia with Lewy Bodies?1. Journal of Alzheimer's Disease, 2018, 65, 207-219.	1.2	4
15	Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies. Genes, 2018, 9, 63.	1.0	25
16	Size-Exclusion Chromatography-based isolation minimally alters Extracellular Vesiclesâ€™ characteristics compared to precipitating agents. Scientific Reports, 2016, 6, 33641.	1.6	385
17	GBA Mutations Are Associated With Earlier Onset and Male Sex in Dementia With Lewy Bodies. Movement Disorders, 2016, 31, 1066-1070.	2.2	34
18	Highlights from the latest articles in biomarkers in medicine. Biomarkers in Medicine, 2015, 9, 9-11.	0.6	0

#	Article	IF	Citations
19	Cystatin <scp>C</scp> is differentially involved in multiple system atrophy phenotypes. Neuropathology and Applied Neurobiology, 2015, 41, 507-519.	1.8	7
20	In Situ Measurements of Hydrogen Diffusion in Duplex Stainless Steels by Neutron Radiography. , 2014, , 155-163.		1
21	The advantage of using in-situ methods for studying hydrogen mass transport: Neutron radiography vs. carrier gas hot extraction. International Journal of Hydrogen Energy, 2013, 38, 14725-14729.	3.8	13
22	Alpha-Synuclein Posttranslational Modification and Alternative Splicing as a Trigger for Neurodegeneration. Molecular Neurobiology, 2013, 47, 509-524.	1.9	112
23	Simpsonâ€“<scp>G</scp>olabiâ€“<scp>B</scp>ehmel Syndrome Type 1 and Hepatoblastoma in a Patient With a Novel Exon 2â€“4 Duplication of the <scp>GPC</scp>3 Gene. American Journal of Medical Genetics, Part A, 2013, 161, 1091-1095.	0.7	20
24	The first genetic biomarker for dementia with Lewy bodies. Biomarkers in Medicine, 2013, 7, 909-911.	0.6	1
25	Dyskinesias as a Limiting Factor in the Treatment of Segawa Disease. Pediatric Neurology, 2012, 46, 404-406.	1.0	17
26	New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases. Neurogenetics, 2012, 13, 61-72.	0.7	17
27	Alpha- and beta-synuclein expression in Parkinson disease with and without dementia. Journal of the Neurological Sciences, 2011, 310, 112-117.	0.3	26
28	Neuropsychiatric symptoms and intelligence quotient in autosomal dominant Segawa disease. Journal of Neurology, 2011, 258, 2155-2162.	1.8	31
29	The decrease of Î²-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. Brain, 2010, 133, 3724-3733.	3.7	35
30	Molecular Pathology of Lewy Body Diseases. International Journal of Molecular Sciences, 2009, 10, 724-745.	1.8	101
31	Segawa syndrome due to mutation Q89X in the GCH1 gene: a possible founder effect in CÃ³rdoba (southern Spain). Journal of Neurology, 2009, 256, 1816-1824.	1.8	13
32	Primary Renal Cell Carcinoma in a Transplanted Kidney: Genetic Evidence of Recipient Origin. Transplantation, 2009, 87, 1057-1061.	0.5	34
33	Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics, 2008, 9, 15-23.	0.7	70
34	Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics, 2008, 9, 163-172.	0.7	76
35	The Therapeutical Potential of Alpha-Synuclein Antiaggregatory Agents for Dementia with Lewy Bodies. Current Medicinal Chemistry, 2008, 15, 2748-2759.	1.2	22
36	Protein Aggregation Mechanisms in Synucleinopathies: Commonalities and Differences. Journal of Neuropathology and Experimental Neurology, 2007, 66, 965-974.	0.9	60

#	Article	IF	Citations
37	A variable poly-T sequence modulates Î±-synuclein isoform expression and is associated with aging. Journal of Neuroscience Research, 2007, 85, 1538-1546.	1.3	19
38	Parkin and synphilin-1 isoform expression changes in Lewy body diseases. Neurobiology of Disease, 2007, 26, 681-687.	2.1	31
39	Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. NeuroReport, 2006, 17, 1327-1330.	0.6	47
40	Î±-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathologica, 2006, 112, 237-251.	3.9	179
41	Age at Onset: An Essential Variable for the Definition of Genetic Risk Factors for Sporadic Alzheimer's Disease. Annals of the New York Academy of Sciences, 2005, 1057, 260-278.	1.8	186
42	Genetic Contribution to Aging: Deleterious and Helpful Genes Define Life Expectancy. Annals of the New York Academy of Sciences, 2005, 1057, 50-63.	1.8	10
43	Age at Onset: An Essential Variable for the Definition of Genetic Risk Factors for Sporadic Alzheimer's Disease. Annals of the New York Academy of Sciences, 2005, 1057, 260-278.	1.8	1
44	Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease. Current Alzheimer Research, 2004, 1, 127-133.	0.7	45
45	Differential expression of Î±-synuclein isoforms in dementia with Lewy bodies. Neuropathology and Applied Neurobiology, 2004, 30, 601-607.	1.8	62
46	The homocysteine pathway: A new target for Alzheimer disease treatment?. Drug Development Research, 2004, 62, 221-230.	1.4	5
47	Upregulation of amyloid precursor protein isoforms containing Kunitz protease inhibitor in dementia with Lewy bodies. Molecular Brain Research, 2004, 131, 131-135.	2.5	15
48	Methionine synthase polymorphism is a risk factor for Alzheimer disease. NeuroReport, 2003, 14, 1391-1394.	0.6	19
49	Methionine synthase polymorphism is a risk factor for Alzheimer disease. NeuroReport, 2003, 14, 1391-1394.	0.6	34
50	The Th1/E47cs-G apolipoprotein E (APOE) promoter allele is a risk factor for Alzheimer disease of very later onset. Neuroscience Letters, 2002, 326, 187-190.	1.0	14
51	Alzheimerâ€™s disease and the cystatin C gene polymorphism: an association study. Neuroscience Letters, 2001, 315, 17-20.	1.0	64
52	Apolipoprotein E genotypes and age at onset of Parkinson's disease. Annals of Neurology, 1998, 44, 294-295.	2.8	9
53	A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late-onset Alzheimer's disease. Neurogenetics, 1998, 1, 293-296.	0.7	42
54	APOE ?4 Allele Frequency in Alzheimer's Disease and Vascular Dementia in the Spanish Population. Annals of the New York Academy of Sciences, 1997, 826, 452-455.	1.8	5